

Review Article

Cytoskeletal Pathologies of Alzheimer Disease

James R. Bamberg^{1*} and George S. Bloom²

¹*Department of Biochemistry and Molecular Biology, Molecular, Cellular and Integrative Neuroscience Program, Colorado State University, Fort Collins, Colorado*

²*Departments of Biology and Cell Biology, University of Virginia, Charlottesville, Virginia*

The histopathological hallmarks of Alzheimer disease are the extracellular amyloid plaques, composed principally of the amyloid beta peptide, and the intracellular neurofibrillary tangles, composed of paired helical filaments of the microtubule-associated protein, tau. Other histopathological structures involving actin and the actin-binding protein, cofilin, have more recently been recognized. Here we review new findings about these cytoskeletal pathologies, and, emphasize how plaques, tangles, the actin-containing inclusions and their respective building blocks may contribute to Alzheimer pathogenesis and the primary behavioral symptoms of the disease. *Cell Motil. Cytoskeleton* 66: 635–649, 2009. © 2009 Wiley-Liss, Inc.

Key words: Alzheimer disease; tau; microtubule; actin; cofilin; amyloid beta

ALZHEIMER DISEASE

Historical Aspects and Definition

Alzheimer Disease (AD) is currently diagnosed post mortem where the pathology found in brains is largely stereotypical and includes extracellular amyloid plaques and intracellular neurofibrillary tangles (NFTs). Late stages of AD are characterized by hallucinations, paranoia, loss of verbal communication, loss of fine and later gross motor control often resembling Parkinson's disease, incontinence, and finally the patient lapses into a vegetative state where they remain until death. However, AD presents clinically as a steady decline in cognitive ability beginning with the loss of short-term memory and progressing through stages of increasing dementia. The severity of the symptoms varies dramatically among individuals and the time of progression through these stages may take anywhere from months to years.

Hallmarks of AD: Senile Plaques, Neurofibrillary Tangles, and Cofilin Pathology

The amyloid, or senile, plaques are composed mainly of fibrils formed by amyloid beta (A β) peptides, whereas the NFTs principally comprise paired helical filaments (PHFs) made from the microtubule binding

Contract grant sponsor: NIH; Contract grant numbers: NS40371, NS43115, and NS051764.

*Correspondence to: James R. Bamberg, Department of Biochemistry and Molecular Biology, 1870 Campus Delivery, Colorado State University, Fort Collins, CO 80523-1870, USA.
E-mail: jrbamberg@lamar.colostate.edu

Received 4 March 2009; Accepted 29 April 2009

Published online 28 May 2009 in Wiley InterScience (www.interscience.wiley.com).
DOI: 10.1002/cm.20388

and stabilizing protein, tau. Hirano bodies, paracrystalline intracellular inclusions containing actin and actin binding proteins, are also a prominent feature of AD brain. However, both amyloid plaques and Hirano bodies are often found in brains of cognitively normal individuals suggesting that they are not the cause of the senile dementia. Other changes in the actin cytoskeleton have been described at synaptic sites as well as non-synaptic sites, which can be grouped and referred to as cofilin pathologies because of changes in cofilin activity or organization.

Blockage in transport that leads to axonal swellings is a common feature of AD brain and is often initiated by specific cytoskeletal alterations that lead to abnormal protein inclusions; the formation and role of these inclusions in AD will be one focus of this review.

Genetic Causes of Familial AD: The Amyloid Hypothesis

Proteolytic cleavage of the full-length β -amyloid precursor protein (APP) by β - and γ -secretases gives rise to A β peptides ranging in length from 39–43 amino acids which form in part the extracellular senile plaques characteristic of AD [Glennner and Wong, 1984a; Price et al., 1995; Sisodia and Price, 1995; Hardy and Selkoe, 2002; Mattson, 2004; Tanzi and Bertram, 2005]. Mutations that lead to increased production of the more amyloidogenic A β_{1-42} species are linked to early onset familial AD with high penetrance [Chartier-Harlin et al., 1991a,b; Goate et al., 1991; Murrell et al., 1991; Price et al., 1995]. Familial AD mutations have been identified in genes encoding APP, and in presenilins 1 and 2 [Tanzi and Bertram, 2005], components of the γ -secretase complex responsible for one of the proteolytic cleavages that gives rise to amyloid beta peptides. Furthermore, Down syndrome (DS; aka trisomy 21) patients living to age 40 or beyond develop all of the pathological hallmarks of AD [Glennner and Wong, 1984b]. Chromosome 21 carries genes for both APP and a β -secretase (BACE-2), and DS patients have increased expression of both [Cataldo et al., 2003]. The BACE-2 gene has been excluded as a contributor to the pathogenesis of AD in DS patients, but an increase in BACE-1 activity, which occurs in DS patients, does contribute [Sun et al., 2006a,b]. Although the molecular mechanism increasing BACE-1 activity has not been elucidated, it could arise as a result of increased expression of two other genes, named DSCR1 and DYRK1A, which lie within the critical region of chromosome 21; the products of these genes act synergistically to prevent nuclear occupancy of NFATc transcription factors [Arron et al., 2006]. BACE1 expression is regulated at least in part by NFATc which binds to several DNA sequences in the BACE1 promoter region [Cho et al., 2008]. Additionally

expression of a common polymorphism (ϵ 4) found in apolipoprotein-E (ApoE) has been correlated with increased risk for late-onset AD [Schmechel et al., 1993; Strittmatter et al., 1993], shifting the onset age almost 10 years earlier in individuals homozygous for the ϵ 4 allele [Numomura et al., 1996]. Interestingly, the size of the amyloid plaques did not increase in AD patients with the ϵ 4 allele versus those with the ϵ 3 allele, but rather plaque numbers increased, suggesting enhanced nucleation of plaque formation [Hyman et al., 1995]. The “amyloid hypothesis” states that increasing cerebral accumulation of A β over years to decades exacerbates cognitive decline, neurodegeneration, and senile plaque deposition associated with AD and can be a result of mutations or allele expression patterns (or both) that enhance production/aggregation or decreased clearance/degradation of A β .

The concept that different isoforms and/or conformations of A β deliver independent signals to neurons is widely supported. Although the term A β is used to describe a spectrum of peptide species, the neurotoxic effects of different A β peptides are not the same. Investigations are beginning to elucidate differences in the biological activity of A β species. Amyloid β_{1-40} fibrils (fA β_{1-40}) induce dystrophy in cultured cortical neurons, at least in part via activation of focal adhesion proteins [Busciglio et al., 1992; Grace et al., 2002; Grace and Busciglio, 2003]. Treatment of human cortical neurons with 20 μ M fA β_{1-40} for 10 days produced progressive dystrophy and minimal neurotoxicity [Deshpande et al., 2006]. Focal adhesions provide a link to the actin cytoskeleton whereby integrin receptors can activate intracellular signals that regulate actin cytoskeletal dynamics [Giancotti and Ruoslahti, 1999; Calderwood et al., 2000]. However, most research today is focused on the smaller soluble forms of A β and not the insoluble fibrils or large aggregates, whose sequestration into plaques may be neuroprotective.

Soluble species of A β (sA β ; also called ADDLs for A β -derived diffusible ligands) bind to synaptic sites on cultured hippocampal neurons [Gong et al., 2003; Lacor et al., 2004]. Furthermore, ADDLs derived from synthetic A β are toxic to cultured neurons at nanomolar concentrations [Lambert et al., 1998] and at 500 nM they prevent high frequency stimulation-induced LTP measured from the dentate gyrus in acute hippocampal slices [Wang et al., 2002]. sA β has been linked to hippocampus-dependent temporal memory deficits in mice [Ohno et al., 2006]. Transgenic mice expressing mutant forms of human APP and presenilin-1 (Tg6799) or human mutant APP alone (Tg2675) both display elevated levels of sA β and temporal memory deficits [Ohno et al., 2006]. Deletion of the BACE1 gene lowered the concentration of sA β to wild type levels and rescued temporal memory

deficits in Tg6799 mice, implying a direct role of A β formation in memory loss.

Recent work has identified a soluble form of A β with the chromatographic and electrophoretic properties of peptide dimers and trimers as the major species responsible for the synaptic deficits characteristic of AD [Shankar et al., 2007; Shankar et al., 2008]. The A β -dimer has been extracted from human AD and DS brains but not from brains of patients with other forms of dementia that are unrelated to A β production [Shankar et al., 2008]. Furthermore, the A β -dimer causes synaptic dysfunction at subnanomolar concentrations, which are 10^3 – 10^5 fold lower than what is commonly used for *in vitro* assays with fibrils or with oligomeric forms of synthetic A β . The assembly of synthetic A β into oligomers or fibrils is so rapid at the typically used concentrations that little remains of the smaller, more pathophysiologically active species [Hung et al., 2008]. Thus, the dimer/trimer fraction of amyloid beta that is secreted from cultured 7PA2 cells, which stably express a mutated, pathogenic form of human APP [Walsh et al., 2002], or the dimer fraction isolated from postmortem human AD brain, contain the more physiologically relevant species at close to their naturally occurring concentrations [Cleary et al., 2005; Shankar et al., 2008]. Single infusions of either of these fractions into adult rat brain cause transient memory and learning deficits [Cleary et al., 2005; Shankar et al., 2008]. Treatment of hippocampal slices in culture with these same fractions give rise to decreased long-term potentiation (LTP) and enhanced long-term depression (LTD), electrophysiological correlates of the learning and memory defects in the intact animal [Shankar et al., 2008].

Possible Causes of Sporadic AD

The vast majority of AD is sporadic with familial AD (FAD) accounting for fewer than 5% of all cases [Mattson, 2004; Tanzi and Bertram, 2005]. One of the major challenges in AD research is to identify causative factors, other than the few point mutations known to induce A β accumulation in FAD, which will ultimately lead to the same common pathologies observed in sporadic and familial AD brains. Because AD is an age-related disorder, one early focus for its cause was mitochondrial dysfunction due to mitochondrial aging [Fukui and Moraes, 2008]. Mitochondrial dysfunction also allowed for many other initiators of AD that could come from environmental sources, such as mitochondrial poisons (e.g., herbicides and insecticides) that have been implicated in Parkinson Disease [Hatcher et al., 2008]. Mitochondrial dysfunction could itself give rise to the release of reactive oxygen species, initiating oxidative stress, or conversely, other initiators of oxidative stress could lead to mitochondrial dys-

function. Regardless of the initiator, mitochondrial insufficiency in CNS neurons leads to a decline in cellular ATP. Another potential AD initiator is increased extracellular glutamate, the major excitatory neurotransmitter in the CNS. In excess, glutamate can cause neuronal excitotoxicity [Arias et al., 1998; Lancelot and Beal, 1998]. Excess accumulation of glutamate most likely occurs as a function of decreased glial cell uptake and conversion to glutamine for transfer to and re-utilization by neurons. Any of these mechanisms for AD initiation could also be exacerbated by metabolic or age related changes in the cerebrovasculature, which could impact clearance and exchange mechanisms. Indeed there is a significant association between diabetes and dementia [Duron and Hanon, 2008], especially the insulin-resistant type II diabetes that may impact AD through excitotoxicity, aberrant calcium signaling, release of inflammatory cytokines and common signaling cascade intermediates [Zhao and Townsend, 2009]. Furthermore, A β oligomers impair neuronal insulin receptor signaling [Zhao et al., 2008].

For initiators of sporadic AD to ultimately cause the same final pathology seen in FAD, there must also be changes in the amount or form of A β peptides being generated, degraded or cleared from the body as a result of neuronal abnormalities. Because the activity of α -secretase is high in the lipid environment of the plasma membrane and the activity of β -secretase is enhanced in endosomes [Ehehalt et al., 2003], increasing endocytosis of the plasma membrane APP or decreasing the efficiency of transporting the APP-containing endosomes to site where they can fuse with lysosomes and degrade the newly formed A β are likely to enhance production of A β peptides. Although inhibition of APP trafficking by overexpressing tau protein to inhibit motor molecules from moving vesicles on microtubules did not increase the generation of A β peptides [Goldsbury et al., 2006], treatment of cultured neurons with excess glutamate, A β peptide oligomers, or peroxide all caused a blockage in transport [Hiruma et al., 2003; Maloney et al., 2005; Goldsbury et al., 2008], resulting in accumulation of retrogradely transported vesicles containing APP and β -secretase cleaved APP [Maloney et al., 2005] and, in the one case where it was quantified, a 2.5 fold increase in A β peptide secretion [Goldsbury et al., 2008]. These findings suggest that the mechanism of transport inhibition, perhaps one allowing fusion of different endosomal vesicles during blockage and exocytosis, might be required to generate increased A β secretion. *In vivo* such vesicle fusion may be a very slow process. Enlarged early endosomes develop in neurons before birth in DS brains [Cataldo et al., 2003] and appear years before significant formation of A β deposits and

the neurofibrillary pathology associated with AD and DS [Cataldo et al., 1997; Cataldo et al., 2000; Cataldo et al., 2004].

During AD and DS progression, both the size and number of basal forebrain cholinergic (BFC) neurons decrease [Whitehouse et al., 1982; Mann et al., 1984; Casanova et al., 1985; Mufson et al., 1989]. BFC neurons depend upon NGF for their normal function and development. BFC neuronal loss, a classic feature of both AD and DS, results, at least in part, from defective retrograde transport of nerve growth factor (NGF) from the hippocampus [Cooper et al., 2001]. NGF produced in the hippocampus binds to receptors on BFC axons and is retrogradely transported as an active signaling endosome to the cell body [Sofroniew et al., 2001]. This early loss of transport in some axons in AD brain correlates with the appearance of "striated neuropil threads," localized tandem arrays of swellings that occur along a neurite and which are packed with filament bundles, most of which immunostain for the microtubule associated protein tau [Velasco et al., 1998]. Thus abnormal cytoskeletal organization that brings about defects in transport may indeed be an early event in response to a sporadic AD initiator. How such initiators might bring about these changes in cytoskeletal organization is described below.

CYTOSKELETAL PATHOLOGIES

Paired Helical Filaments, Neurofibrillary Tangles, and Tau

Structures corresponding to NFTs were first described more than a century ago by Alois Alzheimer, the discoverer and namesake of the now well known disease [Alzheimer, 1907]. More than 50 additional years passed before electron microscopy revealed that NFTs correspond to densely packed fibers, the PHFs [Kidd, 1963], which subsequently were shown to be ~20 nm in diameter at their widest and of highly variable length [Wischik et al., 1985]. The molecular composition of PHFs was finally resolved in the late 1980s, when tangles were immunolabeled by anti-tau *in situ*, and isolated tangles were found to elicit immune responses against tau, and to comprise a collection of epitopes and peptide sequences spanning virtually the entire tau molecule [Grundke-Iqbal et al., 1986; Kosik et al., 1986; Nukina and Ihara, 1986; Wood et al., 1986; Kondo et al., 1988; Kosik et al., 1988]. Although NFTs have also been reported to be immunoreactive with antibodies to neurofilament subunits [Anderton et al., 1982; Perry et al., 1985] and MAP2 [Kosik et al., 1984], *in vitro* reconstitution experiments established that full length tau or

microtubule-binding tau fragments can self-assemble into straight filaments and PHF-like structures in the absence of any other protein species [Goedert et al., 1996; Kampers et al., 1996; Wilson and Binder, 1997; King et al., 1999]. The microtubule binding region of tau thus appears to be both necessary and sufficient to form the core structure of the PHF.

Human tau is encoded by a single gene [Neve et al., 1986], which is expressed primarily in neurons [Binder et al., 1985; Boyne et al., 1995]. Within the brain, the only organ directly targeted in AD, tau accumulates preferentially in axons [Binder et al., 1985], and is encoded by alternatively spliced transcripts that yield six microtubule-binding isoforms ranging from 352–441 amino acid residues in length [Himmler, 1989] and at least one smaller isoform that lacks the microtubule-binding region [Luo et al., 2004]. The microtubule-binding region begins near the middle of the protein as a proline-rich domain followed C-terminally by three or four imperfect tandem repeats that are encoded by exons 9–12 and comprise 31 or 32 amino acid residues each [Lee et al., 1988; Goedert et al., 1989a,b; Preuss et al., 1997]. Interested readers are referred to the following recent reviews that illustrate and discuss tau gene and protein structure in greater detail [Lee et al., 2001; Andreadis, 2005].

Polymerization into PHFs is not the only pathological response of tau in AD. Relative to tau in normal brain, AD tau is found throughout both the axonal and somatodendritic compartments [Grundke-Iqbal et al., 1986] in hyperphosphorylated [Grundke-Iqbal et al., 1986], C-terminally proteolyzed [Novak et al., 1993; Garcia-Sierra et al., 2001; Gamblin et al., 2003] and oxidized forms, such as the conformationally altered tau recognized by the Alz50 monoclonal antibody [Takeda et al., 2000]. All tau isoforms contain at least 30 phosphorylation sites (reviewed in Buée et al., 2000), most of which are usually in the de-phospho form in normal tau, but many of which are frequently phosphorylated in AD tau [Lee et al., 2001]. Tau phosphorylation, particularly at specific sites, like S262, reduces its affinity for MTs [Biernat et al., 1993], so it is not surprising that considerable attention has been paid to determining which protein kinases and phosphatases control tau phosphorylation. Numerous tau kinases have been found, including, but not restricted to MAPK [Drewes et al., 1992; Goedert et al., 1992], GSK-3 β [Hanger et al., 1992; Mandelkowitz et al., 1992], MARK/PAR-1 [Drewes et al., 1995], and cdk2 and cdk5 [Baumann et al., 1993]. In contrast, PP2A appears to be the major tau phosphatase *in vivo* [Goedert et al., 1995; Sontag et al., 1996; Sontag et al., 1999], although PP1, PP2B and PP2C are also capable of dephosphorylating tau *in vitro* [Buée et al., 2000], and presumably *in vivo* as well.

A common feature of PHFs isolated from AD brain is the presence of C-terminally cleaved tau that ends with a glutamic acid corresponding to position 391 in the largest isoform of human brain tau [Novak et al., 1993]. The protease responsible for cutting tau following E391 has not been identified, but this cleavage event may follow earlier proteolysis that yields tau terminating at D421. Cleavage at this position can be catalyzed by caspases 3, 7 and 8 to yield a truncated tau that assembles in vitro into PHF-like polymers more rapidly and efficiently than full length tau [Gamblin et al., 2003].

AD is the most common, but by no means only disease that involves tau pathology. At least 20 additional neurodegenerative disorders are associated with NFTs, hyperphosphorylated tau, and impaired memory and cognition, but generally not with amyloid pathology [Lee et al., 2001]. Perhaps most notable among these “non-Alzheimer tauopathies” are several that can be caused by tau mutations. Examples of such diseases include FTDP-17 (frontotemporal dementia with Parkinsonism linked to chromosome 17), and syndromes resembling progressive supranuclear palsy, corticobasal degeneration and Pick’s disease [Lee et al., 2001]. Tau mutations cause these non-Alzheimer tauopathies with very high penetrance, but have not been found to be associated with AD. Nevertheless, AD is always associated with the combination of amyloid pathology and tau pathology, whereas amyloid pathology in the absence of tau pathology is usually asymptomatic. It follows naturally that tau lies within a pathway, which if appropriately perturbed, leads with high probability to neurodegeneration, dementia and death.

Abnormalities in the Actin Cytoskeleton

Actin Dynamics and Regulation. The ability of globular actin (G-actin) to rapidly assemble and disassemble into filaments (F-actin) is critical to many cell behaviors. Among the most important regulators of actin dynamics are members of the ADF/cofilin family. Because mammalian neurons contain about 5–10 fold more cofilin than ADF [Minamide et al., 2000; Garvalov et al., 2007], henceforth we will just refer to cofilin. Cofilin can sever filaments and thus form more filament ends. Depending upon the local environment, the newly formed “barbed” ends may enhance nucleation and filament growth or the “pointed” ends may increase subunit dissociation and filament depolymerization (reviewed in Bamberg and Wiggan, 2002]. ADF and cofilin’s ability to increase actin filament dynamics is inhibited by their phosphorylation on ser 3 by LIM kinase and other kinases [Morgan et al., 1993; Agnew et al., 1995; Moriyama et al., 1996; Arber et al., 1998; Yang et al., 1998; Toshima et al., 2001]. The active (dephosphorylated) cofilin, generated by specific and highly regulated phos-

phatases in the slingshot [Niwa et al., 2002; Eiseler et al., 2009] and chronophin [Gohla et al., 2005] families, binds to ADP-actin with higher affinity than to ATP-actin and stabilizes a slightly twisted form of actin [McGough et al., 1997; Galkin et al., 2001]. Persistent filament severing by cofilin is highest at low cofilin/actin ratios where low occupancy of the filaments creates boundaries between different twisted states. At higher cofilin/actin ratios severing is more transient during early stages of filament binding [Chan et al., 2009] and at even higher cofilin/actin ratios cofilin nucleates actin assembly [Chen et al., 2004; Andrianantoandro and Pollard, 2006] and stabilizes filaments from turnover [Andrianantoandro and Pollard, 2006; Bernstein et al., 2006; Chan et al., 2009]. Thus, cofilin’s influence on actin dynamics increases with active cofilin concentration to an optimal value at an intermediate cofilin/actin ratio. Shifting cofilin activity to enhance actin dynamics might require dephosphorylation (activation) in one region of a cell and phosphorylation (inactivation) in another.

During focal adhesion activation a multiprotein complex containing LIMK1 and its upstream activator PAK becomes recruited via P95PKL-mediated binding to paxillin [Turner, 2000; Chen et al., 2005]. Activated paxillin and focal adhesion proteins are found with high frequency associated with senile plaques in human AD brain [Grace and Busciglio, 2003]. *Drosophila* paxillin positively regulates Rac, an activator of PAK, and negatively regulates Rho, thus paxillin is a modulator of the Rho family of GTPases that affect the LIMK pathway and cofilin phosphorylation [Chen et al., 2005]. Greater phosphorylation (inactivation) of cofilin by active LIM kinase in regions of $\text{fA}\beta_{1-40}$ contact with neurons may be responsible for the enhanced assembly of F-actin observed in these regions [Heredia et al., 2006]. However, in some neurons that contact soluble $\text{A}\beta$, cofilin undergoes dephosphorylation leading to cofilin-actin rods.

Cofilin-Actin Rods. Cofilin-actin enriched inclusions are a common pathological feature observed in a broad spectrum of neurodegenerative diseases (reviewed in Maloney and Bamberg, 2007; Bernstein et al., 2009]. These often take the form of rod shaped bundles of filaments (cofilin-actin rods), as irregular aggregates (probably aggresomes), or as cytoplasmic paracrystalline lattices (Hirano bodies). Cofilin-actin rods form rapidly in response to neuronal stress [Minamide et al., 2000; Davis et al., 2009] but it is unclear if rods are intermediates in the formation of the other aggregates. Actin aggresomes may be an intermediate in formation of Hirano bodies via the activity of a macroautophagic pathway that is upregulated in transgenic mouse models of AD [Yu et al., 2005].

Cofilin-actin rods form in the cytoplasm of many types of cultured cells in response to heat shock [Iida and Yahara, 1986; Iida et al., 1986; Nishida et al., 1987;




Fig. 1. Pathological features of human AD brain as seen by electron microscopy. (A) Extracellular amyloid plaque. (B) Tau containing 20 nm wide paired helical filaments; the twisted ribbon-like structure is better seen in the magnified inset. (C) A likely cofilin-actin rod with a morphology identical to those induced in rat brain organotypic slices [Davis et al., 2009]. Inset at higher magnification shows filaments are thinner (8–9 nm) than paired helical filaments. Images were kindly provided by Judy Boyle (A and B) and George Perry and Sandra Siedlak (C).

Ohta et al., 1989; Iida et al., 1992], osmotic stress [Iida and Yahara, 1986; Nishida et al., 1987], and ATP run-down [Bershadsky et al., 1980; Minamide et al., 2000; Ashworth et al., 2003]. In fibroblasts or epithelial cells, rods are generally reversible and do not appear to cause permanent damage to the cell. However, rods form primarily in the axons and dendrites of neurons where their clearance is more problematic and their affect on cell function more acute. Neurons stressed by treatment with peroxide, glutamate, or ATP-depleting medium, form rods, usually in tandem arrays within the neurite processes where cofilin and actin concentrations are high [Minamide et al., 2000]. Tandem arrays of cofilin-immunostaining occur in the hippocampus and frontal cortex of human AD but not human control brain [Minamide et al., 2000] and in transgenic mouse models of AD [Maloney et al., 2005]. Rods can be induced in axons and dendrites of rat and mouse hippocampal and cortical neurons in dissociated cultures [Minamide et al., 2000] and in organotypic hippocampal slices [Davis et al., 2009]. Similar filamentous structures have been observed in electron micrographs of human AD brain (S. Siedlak and G. Perry, personal communication; Fig. 1). Rods block transport within neurites [Maloney et al., 2005].

Treatment of cultured rat hippocampal neurons with $A\beta_{1-42}$ induces rod formation in $\sim 20\%$ of the total population [Maloney et al., 2005]. Rod formation in neurons treated with $A\beta_{1-42}$ is slower than for the inducers mentioned above, reaching 50% of the maximum response within 6 h in neurons treated with 1 μM synthetic $A\beta_{1-42}$ oligomers ($sA\beta_{1-42}$), and by 12–24 h when treated with $sA\beta_{1-42}$ at concentrations of 10–100 nM, a

time course similar to the decline in ATP levels observed in human cortical neurons exposed to 100 nM $A\beta$ [Deshpande et al., 2006]. $A\beta$ -treatment causes the dephosphorylation (activation) of cofilin within the soma and neurites of only those neurons that form rods [Maloney et al., 2005]. The $A\beta$ -responsive sub-population of hippocampal neurons is most prominent in the dentate gyrus [Davis et al., 2009]. $A\beta$ -induced rods are reversible and disappear completely by 24 h after washout [Davis et al., 2009], which is in contrast to the persistent rods that form within 24 h of a transient 30 min ATP-depletion and washout. Rod persistence may result from an inadequate recovery of mitochondrial function within affected neurites [Minamide et al., 2000].

Synaptic dysfunction is the most established correlate of cognitive decline in AD [Masliah, 2000; Mucke et al., 2000]. Recent studies using *Aplysia kurodai* neurons found that microinjection of cofilin led to rod formation, synapse loss and, distal to the rod, impairment of synaptic plasticity measured by electrophysiological methods [Jang et al., 2005]. While introducing excess cofilin did not affect the gross morphology of the neuron, a decrease in the number of pre-synaptic varicosities was observed. In addition, excess cofilin impaired both basal synaptic transmission and LTP. Neither cell death nor induction of an apoptotic cascade was found to be responsible for these effects.

In addition to its role in rod formation and transport inhibition, cofilin also has direct effects on the structure and dynamics of the postsynaptic terminals known as dendritic spines. Spine dynamics are driven by the actin cytoskeleton which shows treadmilling within the spine

[Honkura et al., 2008], probably mediated by cofilin and its ability to compete for actin binding with drebrin, an F-actin stabilizing protein [Kojima and Shirao, 2007]. A balance between drebrin and cofilin binding to F-actin seems to be important in modulating spine dynamics. Dendritic spines undergo shape changes in response to stimulation that accompany increased insertion of neurotransmitter receptors, part of synaptic plasticity associated with memory and learning [Carlisle et al., 2008]. These changes are dependent upon transmembrane signals mediated by pathways that directly modulate cofilin activity (see signaling section below). In AD brain, there is a downregulation of upstream modulators of cofilin phosphorylation, which could lead to enhanced cofilin activity and excessive release of drebrin, which also occurs in AD brain [Zhao et al., 2006]. Cofilin-actin rods sequester active cofilin, which could be required for maintaining spine plasticity. Thus, the synaptic dysfunction in human AD brain could result directly from changes in local cofilin regulation within spines, from rod formation sequestering spine cofilin and blocking transport to spines, or from a combination of these effects.

Hirano Bodies. ADF, cofilin and actin are also major components of Hirano bodies [Maciver and Harrington, 1995]. Hirano bodies are unique intracytoplasmic inclusions consisting of a paracrystalline ordered array of parallel regularly spaced 6–10 nm filaments in orthogonal layers encircled by a less structured actin dense region [Schochet and McCormick, 1972; Tomonaga, 1974]. Hirano bodies were first described in patients with amyotrophic lateral sclerosis and Parkinsonism-dementia complex (ALS-PDC) on Guam [Hirano et al., 1968; Hirano, 1994]. Because Hirano bodies are found in aged human brain from individuals with normal cognitive abilities, their link to various ailments in which they occur more frequently is tenuous. These include AD [Gibson and Tomlinson, 1977; Mitake et al., 1997], in which AD patients of the same age as controls displayed a significantly greater number of Hirano bodies [Schmidt et al., 1989]. Although Hirano bodies have been found in multiple areas of the brain, they are most frequently found in Sommer's sector of Ammon's horn [Hirano et al., 1968], a region of the brain where AD neurofibrillary tangles and Pick bodies are also enriched [Hirano, 1994]. Since this brain region is involved in the development of new memories, the formation of inclusion bodies in this region could contribute to the cognitive impairment found in patients of AD, as well as in many other neurodegenerative disorders [Hirano, 1994]. Phalloidin, a probe that recognizes F-actin but not that saturated with cofilin [Minamide et al., 2000], stains Hirano bodies [Galloway et al., 1987]. Hirano bodies also contain epitopes for microtubule-associated proteins, including tau, and the actin-associated proteins,

α -actinin, vinculin, tropomyosin, and ADF/cofilin [Galloway et al., 1987; Peterson et al., 1988; Maciver and Harrington, 1995]. Thus, it is believed that these structures are primarily composed of actin and actin binding proteins. Although the mechanism of Hirano body formation from endogenous proteins is unknown, expression in mammalian cells of a C-terminal (CT) fragment of an actin cross-linking protein from *Dictyostelium discoideum* induces structures morphologically identical to Hirano bodies [Maselli et al., 2002] and has provided a model system for their study [Davis et al., 2008].

SIGNALING PATHWAYS ACTIVATED BY NEURODEGENERATIVE SIGNALS AFFECTING THE CYTOSKELETON

Pathways Involving Tau

AD tau has been known to be hyperphosphorylated for more than 20 years [Grundke-Iqbal et al., 1986], but little is known about the upstream signals that disrupt the normal balance between tau kinases and phosphatases in favor of the former. Although the role of tau phosphorylation in PHF assembly in vivo has prompted much speculation, it is clear from in vitro studies that non-phosphorylated tau is fully capable of polymerizing into PHF-like filaments [Wilson and Binder, 1995; Goedert et al., 1996; Kampers et al., 1996]. Furthermore, assembly of PHF-like filaments in cultured cells appears to be modulated by tau phosphorylation, but does not depend on it [Wang et al., 2007]. Thus, in a purely biochemical sense, phosphorylation of tau is not required for its self-assembly, and the extent, if any, to which phosphorylation promotes tau assembly in the brain in vivo remains to be determined. One idea worth considering takes into account that the tau-tau interaction site in PHFs is coincident with the binding site on tau for microtubules [Goedert et al., 1996]. Because phosphorylation of tau at key sites weakens its affinity for microtubules [Biernat et al., 1993], phosphorylation at those sites might represent a switch from an intracellular environment that is non-permissive for tau self-assembly to one that is permissive [Sontag et al., 1999].

Regardless of how phosphorylation influences tau assembly into PHFs, an equally important issue is how PHFs affect cell behavior. The most direct evidence comes from a recently developed system for assembly of transfected tau fragments into PHF-like structures in neuroblastoma cells. Within a few days after transgene expression begins, appreciable cell death is evident in cultures that express assembly-competent versions of tau, but not in cells expressing tau mutants that fail to self-assemble [Khlistunova et al., 2006; Wang et al.,

2007]. It thus seems likely that tau filaments are inherently cytotoxic.

But must tau assemble into filaments in order to compromise cell function or viability? An emerging body of evidence suggests otherwise. Indeed, it seems that many toxic effects of β -amyloid requires expression of soluble tau [Rapoport et al., 2002; King et al., 2006; Roberson et al., 2007].

The first proof of tau-dependent amyloid toxicity came from a study of cultured primary neurons grown in the presence of fA β 40 [Rapoport et al., 2002]. Over the course of 24–96 h of exposure to the amyloid, neurite retraction and cell death progressively increased in wild type, tau-expressing neurons, and nearly 90% of the cells were dead within 4 days. Accompanying these effects was an increase in the activated form of the MAP kinase, ERK2. Remarkably, none of these responses were observed in comparably treated primary neurons from tau knockout mice unless they were transfected to express tau. These results demonstrate that tau is essential for fA β -induced neurotoxicity, at least in cultured neurons, and reinforce earlier *in vivo* mouse studies placing A β upstream of tau in a pathogenic cascade [Götz et al., 2001; Lewis et al., 2001].

The *in vivo* relevance of these cultured neuron results was recently confirmed by a study of transgenic mice [Roberson et al., 2007]. Compared to wild type mice, hAPP transgenics that expressed endogenous mouse tau at normal levels and overexpressed human APP with a pathogenic mutation had impaired memory and learning, were more susceptible to excitotoxin-induced seizures, and had shorter mean lifespans. Although abundant amyloid plaques accumulated in the brains of these mice, NFT pathology was not evident. The hAPP mice were crossed with tau knockout mice and the hybrids were back-crossed to yield all possible genotypes, which were then evaluated for amyloid pathology, learning, memory, excitotoxin response and viability. Mice that lacked tau but overexpressed the human APP mimicked wild type mice for memory and learning, frequency of excitotoxin-induced seizures and lifespan. In contrast, the lack of tau had no effect on amyloid plaque deposition. Bearing in mind the limitations of modeling human AD in mice, these *in vivo* results imply that tau is required for transducing toxic signals from A β in human AD pathogenesis, and that this occurs independently of tau assembling into PHFs.

Why is tau required for A β toxicity? The answer to this question is far from resolved, but an important clue comes from another recent cultured cell study [King et al., 2006]. Exposure of cells to “pre-fibrillar A β ”, which contained a mixture of monomeric peptides and variably sized A β oligomers, was found to cause microtubule loss within 1–3 h, but only in cells that expressed

tau. This set of results was observed in fibroblasts, which expressed tau by transfection to overcome their normally silent tau gene, and in primary neurons, whose endogenous tau could be reduced to trace levels by siRNA. These results identify tau as an essential component of a microtubule disassembly pathway that is initiated by pre-fibrillar A β . Further work is required to establish whether monomeric A β or any particular subset of A β oligomers can induce microtubule depolymerization, but tau clearly functions downstream of the active A β form(s) in this pathway.

If such a pathway were to operate *in vivo* in the brain, neurons would be the principal cells that experience A β -induced microtubule loss because tau is expressed primarily in neurons [Binder et al., 1985]. Microtubule loss would have the devastating effect of leading directly to synaptic dysfunction or the loss of synaptic connections altogether. This is because virtually all proteins located at the axon terminal are synthesized in or near the neuronal perikaryon, but perform their specialized functions many centimeters away from where they are made [Tytell et al., 1981]. Transport of pre-synaptic terminal proteins across such distances by diffusion would require thousands of years, and to enable axonal transport to occur in a more biologically acceptable time frame of hours to days, neurons use microtubules as high speed intracellular highways [Bloom and Goldstein, 1998]. Microtubules are therefore essential for maintaining synaptic integrity, and the fact that neurons express tau at uniquely high levels make them especially vulnerable to the microtubule-depolymerizing activity of pre-fibrillar A β . Although dendrites are known to support abundant protein synthesis, particularly in their proximal segments, it is easy to imagine how a global reduction or loss of microtubules in neurons could affect the functional integrity not only of pre-synaptic terminals, but of post-synaptic sites as well.

Pathways Mediating Actin Dynamics

Regulating Actin Dynamics in Spines. Previous studies have identified multiple pathways that link cofilin activity to memory and learning. For normal synaptic consolidation at excitatory medial perforant path granule cell synapses in the DG, synthesis of the immediate early gene activity-regulated cytoskeletal-associated protein (Arc) is required [Bramham, 2007]. Arc is induced by brain-derived neurotrophic factor (BDNF) or high frequency stimulation that induces long-term potentiation (LTP) in the rat DG *in vivo*. The Arc mRNA is transported into dendrites where it is translated. Prolonged synthesis of Arc leads to phosphorylation (inactivation) of cofilin and decreased cofilin activity is suggested to cause a local expansion of actin filament structures and synaptic stabilization [Bramham, 2007]. Spine architec-

ture is regulated through actin dynamics downstream of the GTPase activating protein SynGAP, which has recently been shown to regulate both steady-state and activity-dependent cofilin phosphorylation [Carlisle et al., 2008].

In an opposing pathway, A β has been shown to down regulate the expression of Pak1 [Zhao et al., 2006]. The presence of bifurcating pathways to activate both phosphorylation and dephosphorylation of cofilin may be necessary to spatially regulate cofilin activity through a cycle of phosphorylation and dephosphorylation in response to a single extracellular ligand. Evidence for bifurcating pathways leading to cofilin phosphocycling was first obtained in serum stimulated fibroblasts [Meberg et al., 1998], but also has been reported in neuronal growth cone pathfinding in gradients of bone morphogenic protein 7 [Wen et al., 2007]. Thus, its importance in dendritic spine morphology in response to glutamate signaling through the NMDA receptor [Carlisle et al., 2008], a known synaptic target of A β [DeFelice et al., 2007], suggests that rapid effects on brain slice electrophysiology by A β extracted from human AD brain [Shankar et al., 2008], could arise from modulation of cofilin activity in spines.

As mentioned earlier, excess active cofilin will displace the actin filament stabilizing protein drebrin from spines, which alters spine dynamics [Kojima and Shirao, 2007]. Drebrin levels are reduced in brains of patients with AD and Down syndrome [Shim and Lubec, 2002], especially in regions where cofilin is activated [Zhao et al., 2006]. Thus the activation of cofilin that occurs within the DG in response to treatment with A β ₁₋₄₂ oligomers may cause rapid alterations in synaptic function through its direct effects on the dynamics of the actin core of spines, perhaps mediated by the Ras family GTPase SynGAP [Carlisle et al., 2008], or through formation of rods within the neurite. Rod formation has the dual property of blocking delivery of material required for normal spine function and sequestering cofilin so that it is less able to participate in spine dynamics.

Rod Formation. Pathways mediating neuronal rod formation from several different rod-inducing stimuli have been partially elucidated. ATP-depletion causes the release of the cofilin phosphatase chronophin (CIN) from Hsp90 [Huang et al., 2008]. CIN is inhibited when bound to Hsp90 so its release causes a net dephosphorylation of cofilin. The Hsp90 inhibitor 17AAG, a geldanamycin analog, also causes the release of CIN from Hsp90, again activating cofilin and leading to rod formation in neurons that are so treated. Silencing of CIN in neurons with siRNA decreases the rate and extent of rod formation in response to both ATP-depletion and 17AAG, but does not eliminate it [Huang et al., 2008], suggesting that

other phosphatases may eventually be recruited for this purpose.

The A β ₁₋₄₂ signaling pathways may not be identical in all neurons and are likely complex. A conditional brain knock-out of *cdc42* was previously shown to be inhibitory to axonogenesis and to increase the pool of phosphorylated cofilin [Garvalov et al., 2007]. Knock-out of *cdc42* or inhibition of *cdc42* activity by dominant negative *cdc42* expression reduced by about 50% the percentage of neurons forming rods in cells treated with 1 μ M synthetic A β ₁₋₄₂ [Davis et al., 2009], suggesting that extracellular A β ₁₋₄₂ activates cofilin in a subpopulation of hippocampal neurons through multiple pathways, only one of which requires *cdc42*.

Cofilin pathology in both AD and DS is spatially and temporally associated with marked reduction of PAK protein levels and activity [Zhao et al., 2006]. In postmortem human and Tg2576 mouse brains, activated phospho-PAK (pPAK) immunostaining resembles staining of intraneuronal A β ₁₋₄₂ that accumulates along with APP-carboxy-terminal fragments (APP-CTFs) within enlarged endosomal and lysosomal structures [Yang et al., 1995; Zhao et al., 2006]. Persistent reduction in pPAK was observed as early as 2 h following treatment of dissociated rat hippocampal neurons with soluble A β ₁₋₄₂ oligomers and occurred at synthetic A β oligomer concentrations as low as 10 nM [Zhao et al., 2006]. Pak1, an effector of the GTP-bound form of *cdc42*, is an activator of LIM kinase [Edwards et al., 1999], which keeps cofilin in an inactive state; thus depletion of Pak1 may result in an over activation of cofilin [Zhao et al., 2006]. Application of a PAK inhibitory peptide to cultured neurons induced the formation of cofilin rods. Intracerebroventricular (i.c.v.) injection of this peptide into wild type mice induced rod-like cofilin pathology and social recognition memory deficits [Zhao et al., 2006]. These findings suggest that a loss of pPAK may lead to local pathology related to the formation of cofilin aggregates similar to those observed in human AD and Tg2576 mouse brain, and may contribute to impaired cognitive function. However, the mechanism by which this occurs in AD brain is not yet clear. LIM kinase is activated by phosphorylation by either PAK or the rho-activated kinase, Rock. A decline in active (phosphorylated) PAK occurs in *cdc42* knockout brain but surprisingly is accompanied by an increase in phosphorylated (active) LIM kinase and phospho-cofilin [Garvalov et al., 2007]. Although in chick retinal neurons activation of *cdc42* leads to cofilin dephosphorylation through inhibition of a ROCK-dependent pathway [Chen et al., 2006], in *cdc42* knockout mouse brains Rho and Rock activity do not appear to change. Thus the mechanism by which LIMK becomes activated is unknown. *Cdc42* null neurons also have a decreased cofilin-specific phospho-

tase activity [Garvalov et al., 2007], which could also contribute to the increased phospho-cofilin pool, and presumably could also enhance the phosphorylated LIM kinase pool since at least one cofilin phosphatase, slingshot 1L, has been shown to dephosphorylate both [Soosairajah et al., 2005].

RELATIONSHIPS AMONG A β , NEUROFIBRILLARY TANGLES, AND COFILIN-ACTIN RODS

Major unresolved questions in AD research pertain to the interrelationships between the different pathologies. Do A β dimers or other forms of A β initiate the cofilin and tau pathologies that affect intracellular transport and synaptic dysfunction? Do the changes in intracellular transport alter APP processing leading to enhanced production, dimerization, and/or secretion of A β that can spread the zone of degeneration? Are pathways for tau hyperphosphorylation and cofilin dephosphorylation (activation) related and does one precede the other? Answers to some of these questions are actively being pursued and may ultimately change the way we think about how AD pathology develops.

In the brains of flies carrying the mutant human tauR406W transgene and in the brains of mice carrying the mutant human tauP301L transgene, both of which are linked to fronto-temporal dementia, cofilin-actin rods are observed to co-localize with tau deposits that stain for phosphorylated tau species associated with paired helical filaments [Fulga et al., 2007]. Human mutant tau has the ability to bind and bundle F-actin *in vitro* and it could be responsible for the formation of actin bundles observed in cells. However, the *in vitro* bundles were formed in the presence of phalloidin [Fulga et al., 2007]; phalloidin competes with cofilin for binding actin [Hayden et al., 1993] and fluorescent phalloidins will not stain cofilin-actin rods induced in dissociated neurons or organotypic hippocampal slice [Minamide et al., 2000; Davis et al., 2009]. Thus, *in vivo* we still do not know if mutant human tau is the inducer of actin reorganization or if cofilin-actin rods, formed as a result of the stress of mutant tau expression, serve as a sink for binding the tau. The answer to this question could be extremely important in designing therapeutics. Soluble forms of synthetic A β -oligomers as well as soluble A β -extracts from human AD brain induce AD type of tau hyperphosphorylation in cultured neurons [DeFelice et al., 2008]. One of the earliest pathological features within the brains of AD patients is a tandem array of axonal swellings called "striated neuropil threads." These structures immunostain for tau epitopes [Velasco et al., 1998] but they have the pattern of formation and the size of stress-induced cofilin-actin rods, such as those induced by A β [Maloney et al., 2005]. They could represent an early link between

cofilin and tau pathologies [Whiteman et al., 2008]. Regardless of whether tau is required for A β -induced actin rod formation, axonal transport is likely to be severely compromised by both the tau-dependent microtubule loss and cofilin-actin rod assembly that can be induced by certain forms of A β . It is therefore worth considering the possibility that onset of these cytoskeletal defects represent seminal cell biological events in AD pathogenesis.

ACKNOWLEDGMENTS

The authors gratefully acknowledge the support from the National Institutes of Neurological Diseases and Stroke, NIH, (J.R.B. and G.S.B.), The Alzheimer's Association (G.S.B.), The Owens Family Foundation (G.S.B.), and the Ivy Fund (G.S.B.). The authors thank Chi Pak for helpful comments and discussions and Judy Boyle, Colorado State University and Sandra Siedlak and George Perry, University of Texas at San Antonio for the electron micrographs.

REFERENCES

- Agnew BJ, Minamide LS, Bamburg JR. 1995. Reactivation of phosphorylated actin depolymerizing factor and identification of the regulatory site. *J Biol Chem* 270:17582–17587.
- Alzheimer A. 1907. Über eine eigenartige Erkrankung der Hirnrinde. *Allgemeine Zeitschrift für Psychiatrie und phychisch-Gerichtliche Medizin, Berlin*. 64:146–148.
- Anderton BH, Breinburg D, Downes MJ, Green PJ, Tomlinson BE, Ulrich J, Wood JN, Kahn J. 1982. Monoclonal antibodies show that neurofibrillary tangles and neurofilaments share antigenic determinants. *Nature* 298:84–86.
- Andreadis A. 2005. Tau gene alternative splicing: expression patterns, regulation and modulation of function in normal brain and neurodegenerative diseases. *Biochim Biophys Acta* 1739:91–103.
- Andrianantoandro E, Pollard TD. 2006. Mechanism of actin filament turnover by severing and nucleation at different concentrations of ADF/cofilin. *Mol Cell* 24:13–23.
- Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P. 1998. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. *Nature* 393:805–809.
- Arias C, Becerra-Garcia F, Tapia R. 1998. Glutamic acid and Alzheimer's disease. *Neurobiology (Bp)* 6:33–43.
- Arron JR, Winslow MM, Poller A, Chang CP, Wu H, Gao X, Neilson JR, Chen L, Heit JJ, Kim SK, Yamasaki N, Miyakawa T, Francke U, Graef IA, Crabtree GR. 2006. NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21. *Nature* 441:595–600.
- Ashworth SL, Southgate EL, Sandoval RM, Meberg PJ, Bamburg JR, Molitoris BA. 2003. ADF/cofilin mediates actin cytoskeletal alterations in LLC-PK cells during ATP depletion. *Am J Physiol Renal Physiol* 284:F852–F862.
- Bamburg JR, Wiggan OP. 2002. ADF/cofilin and actin dynamics in disease. *Trends Cell Biol* 12:598–605.
- Baumann K, Mandelkow EM, Biernat J, Pivnicka-Worms H, Mandelkow E. 1993. Abnormal Alzheimer's-like phosphorylation of

- tau protein by cyclin-dependent kinases cdk2 and cdk5. *FEBS Lett* 335:171–175.
- Bernstein BW, Chen H, Boyle JA, Bamberg JR. 2006. Formation of actin-ADF/cofilin rods transiently retards decline of mitochondrial potential and ATP in stressed neurons. *Am J Physiol Cell Physiol* 291:C828–C839.
- Bernstein BW, Maloney MT, Bamberg JR. Actin and diseases of the nervous system. In: Gallo G, Lanier LL, editors. *Neurobiology of Actin*. Springer. In press.
- Bershadsky AD, Gelfand VI, Svitkina TM, Tint IS. 1980. Destruction of microfilament bundles in mouse embryo fibroblasts treated with inhibitors of energy metabolism. *Exp Cell Res* 127:421–429.
- Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow E. 1993. Phosphorylation of ser²⁶² strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. *Neuron* 11:153–163.
- Binder LI, Frankfurter A, Rebhun LI. 1985. The distribution of tau in the nervous system. *J Cell Biol* 101:1371–1378.
- Bloom GS, Goldstein LSB. 1998. Cruising along microtubule highways: how membranes move through the secretory pathway. *J Cell Biol* 140:1277–1280.
- Boyne LJ, Tessler A, Murray M, Fischer I. 1995. Distribution of Big tau in the central nervous system of the adult and developing rat. *J Comp Neurol* 358:279–293.
- Bramham CR. 2007. Control of synaptic consolidation in the dentate gyrus: mechanisms, functions, and therapeutic implications. *Prog Brain Res* 163:453–471.
- Buée L, Bussiere T, Buée-Scherrer V, Delacourte A, Hof PR. 2000. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. *Brain Res Rev* 33:95–130.
- Busciglio J, Lorenzo A, Yankner BA. 1992. Methodological variables in the assessment of beta amyloid neurotoxicity. *Neurobiol Aging* 13:609–612.
- Calderwood DA, Shattil SJ, Ginsberg MH. 2000. Integrins and actin filaments: reciprocal regulation of cell adhesion and signaling. *J Biol Chem* 275:22607–22610.
- Carlisle HJ, Manzerra P, Marcora E, Kennedy MB. 2008. SynGAP regulates steady-state and activity-dependent phosphorylation of cofilin. *J Neurosci* 28:13673–13683.
- Casanova MF, Walker LC, Whitehouse PJ, Price DL. 1985. Abnormalities of the nucleus basalis in Down's syndrome. *Ann Neurol* 18:310–313.
- Cataldo AM, Barnett JL, Pieroni C, Nixon RA. 1997. Increased neuronal endocytosis and protease delivery to early endosomes in sporadic Alzheimer's disease: neuropathologic evidence for a mechanism of increased beta-amyloidogenesis. *J Neurosci* 17:6142–6151.
- Cataldo AM, Peterhoff CM, Troncoso JC, Gomez-Isla T, Hyman BT, Nixon RA. 2000. Endocytic pathway abnormalities precede amyloid- β deposition in sporadic Alzheimer's disease and Down syndrome. Differential effects of ApoE genotype and presenilin mutations. *Am J Pathol* 157:277–286.
- Cataldo AM, Petanceska S, Peterhoff CM, Terio NB, Epstein CJ, Villar A, Carlson EJ, Staufienbiel M, Nixon RA. 2003. APP gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. *J Neurosci* 23:6788–6792.
- Cataldo AM, Petanceska S, Terio NB, Peterhoff CM, Durham R, Mercken M, Mehta PD, Buxbaum J, Haroutunian V, Nixon RA. 2004. Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. *Neurobiol Aging* 25:1263–1272.
- Chan C, Beltzner CC, Pollard TD. 2009. Cofilin dissociates Arp2/3 complex and branches from actin filaments. *Curr Biol* 19:537–545.
- Chartier-Harlin MC, Crawford F, Hamandi K, Mullan M, Goate A, Hardy J, Backhovens H, Martin JJ, Broeckhoven CV. 1991a. Screening for the beta-amyloid precursor protein mutation (APP717: Val-Ile) in extended pedigrees with early onset Alzheimer's disease. *Neurosci Lett* 129:134–135.
- Chartier-Harlin MC, Crawford F, Houlden H, Warren A, Hughes D, Fidani L, Goate A, Rossor M, Roques P, Hardy J, Mullan M. 1991b. Early-onset Alzheimer's disease caused by mutations at codon 717 of the beta-amyloid precursor protein gene. *Nature* 353:844–846.
- Chen H, Bernstein BW, Sneider JM, Boyle JA, Minamide LS, Bamberg JR. 2004. In vitro activity differences between proteins of the ADF/cofilin family define two distinct subgroups. *Biochemistry* 43:7127–7142.
- Chen GC, Turano B, Ruest PJ, Hagel M, Settleman J, Thomas SM. 2005. Regulation of Rho and Rac signaling to the actin cytoskeleton by paxillin during Drosophila development. *Mol Cell Biol* 25:979–987.
- Chen TJ, Gehler S, Shaw AE, Bamberg JR, Letourneau PC. 2006. Cdc42 participates in regulation of ADF/cofilin and retinal growth cone filopodia by brain derived neurotrophic factor. *J Neurobiol* 66:103–114.
- Cho HJ, Jim SM, Youn HD, Huh K, Mook-Jung I. 2008. Disrupted intracellular calcium regulates BACE1 gene expression via nuclear factor of activated T cells 1 (NFAT1) signaling. *Aging Cell* 7:137–147.
- Cleary JP, Walsh DM, Hofmeister JJ, Shankar GM, Kuskowski MA, Selkoe DJ, Ashe KH. 2005. Natural oligomers of the amyloid-beta protein specifically disrupt cognitive function. *Nat Neurosci* 8:79–84.
- Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC. 2001. Failed retrograde transport of NGF in a mouse model of Down's syndrome: reversal of cholinergic neurodegenerative phenotypes following NGF infusion. *Proc Natl Acad Sci USA* 98:10439–10444.
- Davis RC, Furukawa R, Fehhheimer M. 2008. A cell culture model for investigation of Hirano bodies. *Acta Neuropathol* 115:205–217.
- Davis RC, Maloney MT, Minamide LS, Flynn KC, Stonebraker MA, Bamberg JR. Mapping cofilin-actin rods in stressed hippocampal slices and the role of cdc42 in amyloid β -induced rods. *J Alzheimers Dis*. In press.
- De Felice FG, Velasco PT, Lambert MP, Viola K, Fernandez SJ, Ferreira ST, Klein WL. 2007. Abeta oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the Alzheimer drug memantine. *J Biol Chem* 282:1590–1601.
- De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL. 2008. Alzheimer's disease-type neuronal tau hyperphosphorylation induced by Ab oligomers. *Neurobiol Aging* 29:1334–1347.
- Deshpande A, Mina E, Glabe C, Busciglio J. 2006. Different conformations of amyloid beta induce neurotoxicity by distinct mechanisms in human cortical neurons. *J Neurosci* 26:6011–6018.
- Drewes G, Lichtenberg-Kraag B, Doring F, Mandelkow E-M, Biernat J, Goris J, Doree M, Mandelkow E. 1992. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer-like state. *EMBO J* 11:2131–2138.
- Drewes G, Trinczek B, Illenberger S, Biernat J, Schmitt-Ulms G, Meyer HE, Mandelkow EM, Mandelkow E. 1995. Microtu-

- bule-associated protein/microtubule affinity-regulating kinase (p110^{mark}). *J Biol Chem* 270:7679–7688.
- Duron E, Hanon O. 2008. Vascular risk factors, cognitive decline and dementia. *Vasc Health Risk Manag* 4:363–381.
- Edwards DC, Sanders LC, Bokoch GM, Gill GN. 1999. Activation of LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin cytoskeletal dynamics. *Nat Cell Biol* 1:253–259.
- Ehehalt R, Keller P, Haass C, Thiele C, Simons K. 2003. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. *J Cell Biol* 160:113–123.
- Eiseler T, Doppler H, Yan IK, Kitatani K, Mizuno K, Storz P. 2009. Protein kinase D1 regulates cofilin-mediated F-actin reorganization and cell motility through slingshot. *Nat Cell Biol* 11:545–556.
- Fukui H, Moraes CT. 2008. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality of just an attractive hypothesis. *Trends Neurosci* 31:251–256.
- Fulga TA, Elson-Schwab I, Khurana V, Steinhilb ML, Spiers TL, Hyman BT, Feany MB. 2007. Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo. *Nat Cell Biol* 9:139–148.
- Galkin VE, Orlova A, Lukoyanova N, Wriggers W, Engelman EH. 2001. Actin depolymerizing factor stabilizes an existing state of F-actin and can change the tilt of F-actin subunits. *J Cell Biol* 153:75–86.
- Galloway PG, Perry G, Gambetti P. 1987. Hirano body filaments contain actin and actin-associated proteins. *J Neuropathol Exp Neurol* 46:185–199.
- Gamblin TC, Chen F, Zambrano A, Abraha A, Galagwar S, Guillozet AL, Lu M, Fu Y, Garcia-Sierra F, LaPointe N, Miller R, Berry RW, Binder LI, Cryns VL. 2003. Caspase cleavage of tau: linking amyloid and neurofibrillary tangles in Alzheimer's disease. *Proc Natl Acad Sci USA* 100:10032–10037.
- García-Sierra F, Wischik CM, Harrington CR, Luna-Muñoz J, Mena R. 2001. Accumulation of C-terminally truncated tau protein associated with vulnerability of the perforant pathway in early stages of neurofibrillary pathology of Alzheimer's disease. *J Chem Neuroanat* 22:65–77.
- Garvalov BK, Flynn KC, Neukirchen D, Meyn L, Teusch N, Wu X, Brakebusch C, Bamburg JR, Bradke F. 2007. Cdc42 regulates cofilin during the establishment of neuronal polarity. *J Neurosci* 27:13117–13129.
- Giancotti FG, Ruoslahti E. 1999. Integrin signaling. *Science* 285:1028–1032.
- Gibson PH, Tomlinson BE. 1977. Numbers of Hirano bodies in the hippocampus of normal and demented people with Alzheimer's disease. *J Neurol Sci* 33:199–206.
- Glenner GG, Wong CW. 1984a. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. *Biochem Biophys Res Commun* 120:885–890.
- Glenner GG, Wong CW. 1984b. Alzheimer's disease and Down's syndrome: sharing of a unique cerebrovascular amyloid fibril protein. *Biochem Biophys Res Commun* 122:1131–1135.
- Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, Mant R, Newton P, Rooke R, Roquis P, Talbot C, Pericak-Vance M, Roses A, Williamson R, Rossor M, Owen M, Owen M, Hardy J. 1991. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. *Nature* 349:704–706.
- Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. 1989a. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. *EMBO J* 8:393–399.
- Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RA. 1989b. Multiple forms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. *Neuron* 3:519–526.
- Goedert M, Cohen ES, Jakes R, Cohen P. 1992. p42 map kinase phosphorylation sites in MT-associated protein tau are dephosphorylated by protein phosphatase 2A: implications for Alzheimer's disease. *FEBS Lett* 312:95–99.
- Goedert M, Jakes R, Qi Z, Wang JH, Cohen P. 1995. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates τ protein phosphorylated by proline-directed protein kinases or cyclic-AMP-dependent protein kinase. *J Neurochem* 65:2804–2807.
- Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, Crowther RA. 1996. Assembly of microtubule-associated protein tau into Alzheimer's-like filaments induced by sulphated glycosaminoglycans. *Nature* 383:550–553.
- Gohla A, Birkenfeld J, Bokoch GM. 2005. Chronophin, a novel HAD-type serine protein phosphatase, regulates cofilin-dependent actin dynamics. *Nat Cell Biol* 7:21–29.
- Goldsbury C, Mocanu MM, Thies E, Kaether C, Haass C, Keller P, Biernat J, Mandelkow E, Mandelkow EM. 2006. Inhibition of APP trafficking by tau protein does not increase the generation of amyloid-beta peptides. *Traffic* 7:873–888.
- Goldsbury C, Whiteman IT, Jeong EV, Lim YA. 2008. Oxidative stress increases levels of endogenous amyloid-beta peptides secreted from primary chick brain neurons. *Aging Cell* 7:771–775.
- Gong Y, Chang L, Viola KL, Lacor PN, Lambert MP, Finch CE, Krafft GA, Klein WL. 2003. Alzheimer's disease-affected brain: presence of oligomeric A beta ligands (ADDLs) suggests a molecular basis for reversible memory loss. *Proc Natl Acad Sci USA* 100:10417–10422.
- Götz J, Chen F, van Dorpe R, Nitsch RM. 2001. Formation of neurofibrillary tangles in P301L tau transgenic mice induced by A β 42 fibrils. *Science* 293:1491–1495.
- Grace EA, Busciglio J. 2003. Aberrant activation of focal adhesion proteins mediates fibrillar amyloid beta-induced neuronal dystrophy. *J Neurosci* 23:493–502.
- Grace EA, Rabiner CA, Busciglio J. 2002. Characterization of neuronal dystrophy induced by fibrillar amyloid beta: implications for Alzheimer's disease. *Neuroscience* 114:265–273.
- Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. 1986. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. *Proc Natl Acad Sci USA* 83:4913–4917.
- Hanger DP, Hughes K, Woodgett JR, Brion JP, Anderton BH. 1992. Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation on tau: generation of paired helical filament epitopes and neuronal localization of the kinase. *Neurosci Lett* 147:58–62.
- Hardy J, Selkoe DJ. 2002. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. *Science* 297:353–356.
- Hatcher JM, Pennell KD, Miller GW. 2008. Parkinson's disease and pesticides: a toxicological perspective. *Trends Pharmacol Sci* 29:322–329.
- Hayden SM, Miller PS, Brauweiler A, Bamburg JR. 1993. Analysis of the interactions of actin depolymerizing factor with G- and F-actin. *Biochemistry* 32:9994–10004.
- Heredia L, Helguera P, de Olmos S, Kedikian G, Sola VF, LaFerla F, Staufenbiel M, de Olmos J, Busciglio J, Caceres A, Lorenzo A.

2006. Phosphorylation of actin-depolymerizing factor/cofilin by LIM-kinase mediates amyloid beta-induced degeneration: a potential mechanism of neuronal dystrophy in Alzheimer's disease. *J Neurosci* 26:6533–6542.
- Himmler A. 1989. Structure of the tau gene: alternatively spliced transcripts generate a protein family. *Mol Cell Biol* 9:1389–1396.
- Hirano A. 1994. Hirano bodies and related neuronal inclusions. *Neuropathol Appl Neurobiol* 20:3–11.
- Hirano A, Dembitzer HM, Kurland LT, Zimmerman HM. 1968. The fine structure of some intraganglionic alterations. Neurofibrillary tangles, granulovacuolar bodies and "rod-like" structures as seen in Guam amyotrophic lateral sclerosis and parkinsonism-dementia complex. *J Neuropathol Exp Neurol* 27:167–182.
- Hiruma H, Katakura T, Takahashi S, Ichikawa T, Kawakami T. 2003. Glutamate and amyloid beta-protein rapidly inhibit fast axonal transport in cultured rat hippocampal neurons by different mechanisms. *J Neurosci* 23:8967–8977.
- Honkura N, Matsuzaki M, Noguchi J, Ellis-Davies GC, Kasai H. 2008. The subspine organization of actin fibers regulates the structure and plasticity of dendritic spines. *Neuron* 57:719–729.
- Huang TY, Minamide LS, Bamburg JR, Bokoch GM. 2008. Chronophin mediates an ATP-sensing mechanism of cofilin dephosphorylation and neuronal cofilin-actin rod formation. *Dev Cell* 15:691–703.
- Hung LW, Ciccotosto GD, Giannakis E, Tew DJ, Perez K, Masters CL, Cappai R, Wade JD, Barnham KJ. 2008. Amyloid-beta peptide (A β) neurotoxicity is modulated by the rate of peptide aggregation: A β dimers and trimers correlate with neurotoxicity. *J Neurosci* 28:11950–11958.
- Hyman BT, Wear HL, Rebeck GW, Buldyrev SV, Mantegna RN, Ukleja M, Havlin S, Stanley HE. 1995. Quantitative analysis of senile plaques in Alzheimer disease: observation of log-normal size distribution and molecular epidemiology of differences associated with apolipoprotein E genotype and trisomy 21 (Down syndrome). *Proc Natl Acad Sci USA* 92:3586–3590.
- Iida K, Yahara I. 1986. Reversible induction of actin rods in mouse C3H-2K cells by incubation in salt buffers and by treatment with non-ionic detergents. *Exp Cell Res* 164:492–506.
- Iida K, Iida H, Yahara I. 1986. Heat shock induction of intranuclear actin rods in cultured mammalian cells. *Exp Cell Res* 165:207–215.
- Iida K, Matsumoto S, Yahara I. 1992. The KKRKK sequence is involved in heat shock-induced nuclear translocation of the 18-kDa actin-binding protein, cofilin. *Cell Struct Funct* 17:39–46.
- Jang DH, Han JH, Lee SH, Lee YS, Park H, Lee SH, Kim H, Kaang BK. 2005. Cofilin expression induces cofilin-actin rod formation and disrupts synaptic structure and function in Aplysia synapses. *Proc Natl Acad Sci USA* 102:16072–16077.
- Kampers T, Friedhoff P, Biernat J, Mandelkow EM. 1996. RNA stimulates aggregation of microtubule-associated protein tau into Alzheimer-like paired helical filaments. *FEBS Lett* 399:344–349.
- Khlistunova I, Biernat J, Wang Y, Pickhardt M, von Bergen M, Gazova Z, Mandelkow E, Mandelkow EM. 2006. Inducible expression of Tau repeat domain in cell models of tauopathy: aggregation is toxic to cells but can be reversed by inhibitor drugs. *J Biol Chem* 281:1205–1214.
- Kidd M. 1963. Paired helical filaments in electron microscopy of Alzheimer's disease. *Nature* 197:192–193.
- King ME, Ahuja V, Binder LI, Kuret J. 1999. Ligand-dependent tau filament formation: implications for Alzheimer's disease progression. *Biochem* 38:14851–14859.
- King ME, Kan H-M, Baas PW, Erisir A, Glabe CG, Bloom GS. 2006. Tau-dependent microtubule disassembly initiated by pre-fibrillar β -amyloid. *J Cell Biol* 175:541–546.
- Kojima N, Shirao T. 2007. Synaptic dysfunction and disruption of postsynaptic drebrin-actin complex: a study of neurological disorders accompanied by cognitive deficits. *Neurosci Res* 58:1–5.
- Kondo J, Honda T, Mori H, Hamada Y, Miura R, Ogawara M, Ihara Y. 1988. The carboxyl third of tau is tightly bound to paired helical filaments. *Neuron* 1:827–834.
- Kosik KS, Duffy LK, Dowling MM, Abraham C, McCluskey A, Selkoe DJ. 1984. Microtubule-associated protein 2: monoclonal antibodies demonstrate the selective incorporation of certain epitopes into Alzheimer neurofibrillary tangles. *Proc Natl Acad Sci USA* 81:7941–7945.
- Kosik KS, Joachim CL, Selkoe DJ. 1986. Microtubule-associated protein tau (τ) is a major antigenic component of paired helical filaments in Alzheimer disease. *Proc Natl Acad Sci USA* 83:4044–4048.
- Kosik KS, Orecchio LD, Binder L, Trojanowski JQ, Lee VM-Y, Lee G. 1988. Epitopes that span the tau molecule are shared with paired helical filaments. *Neuron* 1:817–825.
- Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL, Lambert MP, Velasco PT, Bigio EH, Finch CE, Krafft GA, Klein WL. 2004. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. *J Neurosci* 24:10191–10200.
- Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Viola K, Zhang C, Finch CE, Krafft GA, Klein WL. 1998. Diffusible, nonfibrillar ligands derived from A β 1–42 are potent central nervous system neurotoxins. *Proc Natl Acad Sci USA* 95:6448–6453.
- Lancelot E, Beal MF. 1998. Glutamate toxicity in chronic neurodegenerative disease. *Prog Brain Res* 116:331–347.
- Lee G, Cowan N, Kirschner M. 1988. The primary structure and heterogeneity of Tau protein from mouse brain. *Science* 239:285–288.
- Lee VM, Goedert M, Trojanowski JQ. 2001. Neurodegenerative tauopathies. *Ann Rev Neurosci* 24:1121–1159.
- Lewis J, Dickson DW, Lin W-L, Chisholm L, Corral A, Jones G, Yen S-H, Sahara N, Skipper L, Yager D, et al. 2001. Enhanced neurofibrillary degeneration in transgenic mice expressing mutant tau and APP. *Science* 293:1487–1491.
- Luo MH, Tse SW, Memmott J, Andreadis A. 2004. Novel isoforms of tau that lack the microtubule-binding domain. *J Neurochem* 90:340–351.
- Maciver SK, Harrington CR. 1995. Two actin binding proteins, actin depolymerizing factor and cofilin, are associated with Hirano bodies. *Neuroreport* 6:1985–1988.
- Maloney MT, Bamburg JR. 2007. Cofilin-mediated neurodegeneration in Alzheimer's disease and other amyloidopathies. *Mol Neurobiol* 35:21–44.
- Maloney MT, Minamide LS, Kinley AW, Boyle JA, Bamburg JR. 2005. Beta-secretase-cleaved amyloid precursor protein accumulates at actin inclusions induced in neurons by stress or amyloid beta: a feedforward mechanism for Alzheimer's disease. *J Neurosci* 25:11313–11321.
- Mandelkow EM, Drewes G, Biernat J, Gustke N, Van Lint J, Vandenhede JR, Mandelkow E. 1992. Glycogen synthase kinase-3 and the Alzheimer-like state of microtubule-associated protein tau. *FEBS Lett* 314:315–321.
- Mann DM, Yates PO, Marcyniuk B. 1984. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. *Neuropathol Appl Neurobiol* 10:185–207.

- Masliah E. 2000. The role of synaptic proteins in Alzheimer's disease. *Ann N Y Acad Sci* 924:68–75.
- Maselli AG, Davis R, Thomson SAM, Davis RC, Fehhheimer M. 2002. Formation of Hirano bodies in Dictyostelium and mammalian cells induced by expression of a modified form of an actin-crosslinking protein. *J Cell Sci* 115:1939–1949.
- Mattson MP. 2004. Pathways towards and away from Alzheimer's disease. *Nature* 430:631–639.
- McGough A, Pope B, Chiu W, Weeds A. 1997. Cofilin changes the twist of F-actin: implications for actin filament dynamics and cellular function. *J Cell Biol* 138:771–781.
- Meberg PJ, Ono S, Minamide LS, Takahashi M, Bamburg JR. 1998. Actin depolymerizing factor and cofilin phosphorylation dynamics: response to signals that regulate neurite extension. *Cell Motil Cytoskeleton* 39:172–190.
- Minamide LS, Striegl AM, Boyle JA, Meberg PJ, Bamburg JR. 2000. Neurodegenerative stimuli induce persistent ADF/cofilin-actin rods that disrupt distal neurite function. *Nat Cell Biol* 2:628–636.
- Mitake S, Ojika K, Hirano A. 1997. Hirano bodies and Alzheimer's disease. *Kaohsiung J Med Sci* 13:10–18.
- Morgan TE, Lockerbie RO, Minamide LS, Browning MD, Bamburg JR. 1993. Isolation and characterization of a regulated form of actin depolymerizing factor. *J Cell Biol* 122:623–633.
- Moriyama K, Iida K, Yahara I. 1996. Phosphorylation of ser-3 of cofilin regulates its essential function on actin. *Genes Cells* 1:73–86.
- Mucke L, Masliah E, Yu GQ, Mallory M, Rockenstein EM, Tatsuno G, Hu K, Kholodenko D, Johnson-Wood K, McConlogue L. 2000. High-level neuronal expression of abeta 1–42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. *J Neurosci* 20:4050–4058.
- Mufson EJ, Bothwell M, Kordower JH. 1989. Loss of nerve growth factor receptor-containing neurons in Alzheimer's disease: a quantitative analysis across subregions of the basal forebrain. *Exp Neurol* 105:221–232.
- Murrell J, Farlow M, Ghetti B, Benson MD. 1991. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. *Science* 254:97–99.
- Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TA. 1986. Identification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of genes for tau and microtubule-associated protein 2. *Mol Brain Res* 1:271–280.
- Nishida E, Iida K, Yonezawa N, Koyasu S, Yahara I, Sakai H. 1987. Cofilin is a component of intranuclear and cytoplasmic actin rods induced in cultured cells. *Proc Natl Acad Sci USA* 84:5262–5266.
- Niwa R, Nagata-Ohashi K, Takeichi M, Mizuno K, Uemura T. 2002. Control of actin reorganization by Slingshot, a family of phosphatases that dephosphorylate ADF/cofilin. *Cell* 108:233–246.
- Novak M, Kabat J, Wischik CM. 1993. Molecular characterization of the minimal protease resistant tau unit of the Alzheimer's disease paired helical filament. *EMBO J* 12:365–370.
- Nukina N, Ihara Y. 1986. One of the antigenic determinants of paired helical filaments is related to tau protein. *J Biochem* 99:1541–1544.
- Nunomura A, Chiba S, Eto M, Saito M, Makino I, Miyagishi T. 1996. Apolipoprotein E polymorphism and susceptibility to early- and late-onset sporadic Alzheimer's disease in Hokkaido, the northern part of Japan. *Neurosci Lett* 206:17–20.
- Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF. 2006. Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1. *Eur J Neurosci* 23:251–260.
- Ohta Y, Nishida E, Sakai H, Miyamoto E. 1989. Dephosphorylation of cofilin accompanies heat shock-induced nuclear accumulation of cofilin. *J Biol Chem* 264:16143–16148.
- Perry G, Rizzuto N, Autilio-Gambetti L, Gambetti P. 1985. Paired helical filaments from Alzheimer disease patients contain cytoskeletal components. *Proc Natl Acad Sci USA* 82:3916–3920.
- Peterson C, Kress Y, Valle R, Goldman JE. 1988. High molecular weight microtubule-associated proteins bind to actin lattices (Hirano bodies). *Acta Neuropathol (Berl)* 77:168–174.
- Preuss U, Biernat J, Mandelkow EM, Mandelkow E. 1997. The jaws model of tau-microtubule interaction examined in CHO cells. *J Cell Sci* 110 (Part 6):789–800.
- Price DL, Sisodia SS, Gandy SE. 1995. Amyloid beta amyloidosis in Alzheimer's disease. *Curr Opin Neurol* 8:268–274.
- Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A. 2002. Tau is essential to β -amyloid-induced neurotoxicity. *Proc Natl Acad Sci USA* 99:6364–6369.
- Roberson ED, Scarce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T, Gerstein H, Yu GQ, Mucke L. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. *Science* 316:750–754.
- Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD. 1993. Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. *Proc Natl Acad Sci USA* 90:9649–9653.
- Schmidt ML, Lee VM, Trojanowsk JQ. 1989. Analysis of epitopes shared by Hirano bodies and neurofilament proteins in normal and Alzheimer's disease hippocampus. *Lab Invest* 60:513–522.
- Schochet SS, Jr, McCormick WF. 1972. Ultrastructure of Hirano bodies. *Acta Neuropathol (Berl)* 21:50–60.
- Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. 2007. Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. *J Neurosci* 27:2866–2875.
- Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. 2008. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. *Nat Med* 14:837–842.
- Shim KS, Lubec G. 2002. Drebrin, a dendritic spine protein, is manifold decreased in brains of patients with Alzheimer's disease and Down syndrome. *Neurosci Lett* 324:209–212.
- Sisodia SS, Price DL. 1995. Role of the beta-amyloid protein in Alzheimer's disease. *FASEB J* 9:366–370.
- Sofroniew MV, Howe CL, Mobley WC. 2001. Nerve growth factor signaling, neuroprotection, and neural repair. *Annu Rev Neurosci* 24:1217–1281.
- Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. 1996. Regulation of the phosphorylation state and microtubule-binding activity of tau by protein phosphatase 2A. *Neuron* 17:1201–1207.
- Sontag E, Nunbhakdi-Craig V, Lee G, Brandt R, Kamibayashi C, Kuret J, White CL, III, Mumby MC, Bloom GS. 1999. Molecular interactions among protein phosphatase 2A, tau and microtubules: implications for the regulation of tau phosphorylation and the development of tauopathies. *J Biol Chem* 274:25490–25498.
- Soosairajah J, Maiti S, Wiggan O, Sarmiere P, Moussi N, Sarcevic B, Sampath R, Bamburg JR, Bernard O. 2005. Interplay between components of a novel LIM kinase-slingshot phosphatase complex regulates cofilin. *EMBO J* 24:473–486.

- Strittmatter WJ, Saunders AM, Schmechel D, Pericak-Vance M, Enghild J, Salvesen GS, Roses AD. 1993. Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. *Proc Natl Acad Sci USA* 90:1977–1981.
- Sun X, Tong Y, Qing H, Chen CH, Song W. 2006a. Increased BACE1 maturation contributes to the pathogenesis of Alzheimer's disease in Down syndrome. *FASEB J* 20:1361–1368.
- Sun X, He G, Song W. 2006b. BACE2 as a novel APP theta-secretase, is not responsible for the pathogenesis of Alzheimer's disease in Down syndrome. *FASEB J* 20:1369–1376.
- Takeda A, Smith MA, Avila J, Nunomura A, Siedlak SL, Zhu X, Perry G, Sayre LM. 2000. In Alzheimer's disease, heme oxygenase is coincident with Alz50, an epitope of τ induced by 4-hydroxy-2-nonenal modification. *J Neurochem* 75:1234–1241.
- Tanzi RE, Bertram L. 2005. Twenty years of the Alzheimer's disease amyloid hypothesis: a genetic perspective. *Cell* 120:545–555.
- Tomonaga M. 1974. Ultrastructure of Hirano bodies. *Acta Neuropathol (Berl)* 28:365–366.
- Toshima J, Toshima JY, Amano T, Yang N, Narumiya S, Mizuno K. 2001. Cofilin phosphorylation by protein kinase testicular protein kinase 1 and its role in integrin-mediated actin reorganization and focal adhesion formation. *Mol Biol Cell* 12:1131–1145.
- Turner CE. 2000. Paxillin and focal adhesion signaling. *Nat Cell Biol* 2:E231–E236.
- Tytell M, Black MM, Garner JA, Lasek RJ. 1981. Axonal transport: each of the major rate components consist of distinct macromolecular complexes. *Science* 214:179–181.
- Velasco ME, Smith MA, Siedlak SL, Nunomura A, Perry G. 1998. Striation is the characteristic abnormality in Alzheimer disease. *Brain Res* 813:329–333.
- Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ. 2002. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. *Nature* 416:535–539.
- Wang HW, Pasternak JF, Kuo H, Ristic H, Lambert MP, Chromy B, Viola KL, Klein WL, Stine WB, Krafft GA, Trommer BL. 2002. Soluble oligomers of beta amyloid (1–42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus. *Brain Res* 924:133–140.
- Wang YP, Biernat J, Pickhardt M, Mandelkow E, Mandelkow EM. 2007. Stepwise proteolysis liberates tau fragments that nucleate the Alzheimer-like aggregation of full-length tau in a neuronal cell model. *Proc Natl Acad Sci USA* 104:10252–10257.
- Wen Z, Han L, Bamberg JR, Shim S, Ming GL, Zheng JQ. 2007. BMP gradients steer nerve growth cones by a balancing act of LIM kinase and Slingshot phosphatase on ADF/cofilin. *J Cell Biol* 178:107–119.
- Whitehouse PJ, Struble RG, Clark AW, Price DL. 1982. Alzheimer disease: plaques, tangles, and the basal forebrain. *Ann Neurol* 12:494.
- Whiteman IT, Cullen KM, Antao ST, Witting PK, Bamberg JR, Goldsby C. 2008. Mitochondrial dysfunction induces the accumulation of microtubule-associated protein in Alzheimer-like striated neurites. *Mol Biol Cell* 19 (Suppl): Abstract 1069.
- Wilson DM, Binder LI. 1995. Polymerization of microtubule-associated protein tau under near-physiological conditions. *J Biol Chem* 270:24306–24314.
- Wilson DM, Binder LI. 1997. Free fatty acids stimulate the polymerization of tau and amyloid β peptides. *Am J Pathol* 150:2181–2195.
- Wischik CM, Crowther RA, Stewart M, Roth M. 1985. Subunit structure of paired helical filaments in Alzheimer's disease. *J Cell Biol* 100:1905–1912.
- Wood JG, Mirra SS, Pollock NJ, Binder LI. 1986. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (τ). *Proc Natl Acad Sci USA* 83:4040–4043.
- Yang AJ, Knauer M, Burdick DA, Glabe C. 1995. Intracellular A beta 1–42 aggregates stimulate the accumulation of stable, insoluble amyloidogenic fragments of the amyloid precursor protein in transfected cells. *J Biol Chem* 270:14786–14792.
- Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K. 1998. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. *Nature* 393:809–812.
- Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, Mohan PS, Mercken M, Farmery MR, Tjernberg LO, Jiang Y, Duff K, Uchiyama Y, Naslund J, Mathews PM, Cataldo AM, Nixon RA. 2005. Macroautophagy—a novel Beta-amyloid peptide-generating pathway activated in Alzheimer's disease. *J Cell Biol* 171:87–98.
- Zhao L, Ma QL, Calon F, Harris-White ME, Yang F, Lim GP, Morihara T, Ubeda OJ, Ambegaokar S, Hansen JE, Weisbart RH, Teter B, Frautschy SA, Cole GM. 2006. Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease. *Nat Neurosci* 9:234–242.
- Zhao WQ, Townsend M. 2009. Insulin resistance and amyloidogenesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. *Biochim Biophys Acta* 1792:482–496.
- Zhao WQ, De Felice FG, Fernandez S, Chen H, Lambert MP, Quon MJ, Krafft GA, Klein WL. 2008. Amyloid beta oligomers induce impairment of neuronal insulin receptors. *FASEB J* 22:246–260.